Back to top
more

Nivalis Therapeutics, Inc. (NVLS)

(Delayed Data from NSDQ)

$2.40 USD

2.40
25,377

+0.05 (2.13%)

Updated Jul 24, 2017 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Is a Beat in the Cards for ImmunoGen (IMGN) in Q2 Earnings?

ImmunoGen has made significant progress with its ovarian cancer pipeline candidate. Let's see if the company can come up with a beat this earnings season.

    Shire (SHPG) Beats on Q1 Earnings & Sales, Reiterates View

    Shire plc (SHPG) reported first-quarter 2017 earnings of $3.63 per American Depositary Share (ADS), beating the Zacks Consensus Estimate of $3.22 and up 13.8% from the year-ago quarter figure of $3.19.

      AMAG Pharma (AMAG) Incurs Loss in Q1, Revenues Rise Y/Y

      AMAG Pharmaceuticals, Inc. (AMAG) reported adjusted earnings of 99 cents per share in the first quarter of 2017 compared with earnings of 68 cents in the year-ago quarter

        What's in Store for Nivalis (NVLS) this Earnings Season?

        Nivalis Therapeutics, Inc. (NVLS) is expected to report first-quarter 2017 results early next month. Last quarter, the company had a positive surprise of 9.09%.

          Nivalis' (NVLS) Shares Down After Merger Deal with Alpine

          The announcement of Nivalis Therapeutics, Inc.'s (NVLS) merger agreement with a privately-held biotechnology company, Alpine Immune Sciences, Inc. failed to excite investors.

            Bristol-Myers to Not Seek Accelerated Approval for Opdivo+Yervoy

            Bristol-Myers (BMY) won't seek an accelerated approval in the U.S. for the combination of its two immuno-oncology treatments Opdivo plus Yervoy for the first-line lung cancer.

              BioLineRx (BLRX) Starts Cancer Study on BL-8040+Keytruda

              BioLineRx (BLRX) announced the initiation of a second phase IIa study on BL-8040 in combination with Keytruda for the treatment of pancreatic cancer.

                Zoetis (ZTS) Thrives on Product Portfolio, Risks Persist

                On Dec 29, 2016, we issued an updated research report on Zoetis Inc. (ZTS).

                  Tirthankar Chakraborty headshot

                  New Strong Buy Stocks for December 30th

                  Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday